---
figid: PMC4885545__cej-25-65-g002
figtitle: Luteolin (Lut) modulates cancer cell cycle progression
organisms:
- Allium cepa
- Daucus carota
- Capsicum annuum
- Petroselinum crispum
- Apium graveolens Dulce Group
- Perilla frutescens
- Limoniastrum guyonianum
- Helichrysum pamphylicum
- Mus musculus
- Rattus norvegicus
- Gallus gallus
- Opsanus beta
- Homo sapiens
- Canis lupus familiaris
organisms_ner:
- Homo sapiens
- Rattus norvegicus
- Canis lupus familiaris
- Mus musculus
- Gallus gallus
- Drosophila melanogaster
pmcid: PMC4885545
filename: cej-25-65-g002.jpg
figlink: /pmc/articles/PMC4885545/figure/F2/
number: F2
caption: Luteolin (Lut) modulates cancer cell cycle progression. Luteolin’s antiproliferative
  activity is attributed to its ability to inhibit IGF-1 activation, thus preventing
  the phosphorylation of the intracellular IRS-1 and its downstream targets. Furthermore,
  luteolin inhibits IGF-1-mediated PI3K/Akt activation by reducing the expression
  of ERα. Estradiol receptor triggers the PI3K/AKT pathway, mediating FKHR phosphorylation,
  which functionally associates with ERα and forms a FKHR–ERα complex. Inhibiting
  AKT activity reduces phosphorylation of its downstream targets, including p70S6K1,
  GSK-3β, and FKHR. Luteolin suppresses prostate cancer cell proliferation by downregulating
  AR expression. Phosphorylation of the cytoplasmic AR by MAPK and AKT enables AR
  to form dimers and enhances ARE. By contrast, luteolin upregulates the expression
  of PDEF, which acts as an androgen-independent transcriptional activator of the
  prostate-specific antigen promoter. AR, androgen receptor; ARE, androgen response
  element; ER, estrogen receptor; Erk, extracellular signal-regulated kinase; FKHR,
  forkhead transcription factor; FLT3, Fms-like tyrosine kinase 3; GSK-3β, glycogen
  synthase kinase-3β; IGF-1, insulin-like growth factor 1; IRS-1, insulin receptor
  substrate 1; ITD, internal tandem duplications; MAPK, mitogen-activated protein
  kinase; mTOR, mammalian target of rapamycin; PDEF, prostate-derived Ets factor;
  PSAP, prosaposin; TDK, tyrosine kinase domain.
papertitle: Molecular targets of luteolin in cancer.
reftext: Muobarak J. Tuorkey. Eur J Cancer Prev. 2016 Jan;25(1):65-76.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9485447
figid_alias: PMC4885545__F2
figtype: Figure
redirect_from: /figures/PMC4885545__F2
ndex: b86470f9-def7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4885545__cej-25-65-g002.html
  '@type': Dataset
  description: Luteolin (Lut) modulates cancer cell cycle progression. Luteolin’s
    antiproliferative activity is attributed to its ability to inhibit IGF-1 activation,
    thus preventing the phosphorylation of the intracellular IRS-1 and its downstream
    targets. Furthermore, luteolin inhibits IGF-1-mediated PI3K/Akt activation by
    reducing the expression of ERα. Estradiol receptor triggers the PI3K/AKT pathway,
    mediating FKHR phosphorylation, which functionally associates with ERα and forms
    a FKHR–ERα complex. Inhibiting AKT activity reduces phosphorylation of its downstream
    targets, including p70S6K1, GSK-3β, and FKHR. Luteolin suppresses prostate cancer
    cell proliferation by downregulating AR expression. Phosphorylation of the cytoplasmic
    AR by MAPK and AKT enables AR to form dimers and enhances ARE. By contrast, luteolin
    upregulates the expression of PDEF, which acts as an androgen-independent transcriptional
    activator of the prostate-specific antigen promoter. AR, androgen receptor; ARE,
    androgen response element; ER, estrogen receptor; Erk, extracellular signal-regulated
    kinase; FKHR, forkhead transcription factor; FLT3, Fms-like tyrosine kinase 3;
    GSK-3β, glycogen synthase kinase-3β; IGF-1, insulin-like growth factor 1; IRS-1,
    insulin receptor substrate 1; ITD, internal tandem duplications; MAPK, mitogen-activated
    protein kinase; mTOR, mammalian target of rapamycin; PDEF, prostate-derived Ets
    factor; PSAP, prosaposin; TDK, tyrosine kinase domain.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - FLT3
  - IGF1
  - IGF1R
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - IRS1
  - AR
  - AKT1
  - AKT2
  - AKT3
  - ESR1
  - ERAL1
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - SGSM3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - GSK3B
  - EPHB2
  - SPDEF
  - FOXO1
  - MTOR
  - PSAP
  - MTCH1
  - SFTPA1
  - SFTPA2
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - Flt3
  - Igf1
  - Igf1r
  - Pik3cg
  - Irs1
  - Ar
  - Akt1
  - Esr1
  - Gsk3b
  - Ephb1
  - Foxo1
  - Mtor
  - Psap
  - Sftpa1
  - Wnt2
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Eral1
  - Mdk
  - Rps6kb1
  - Ephb2
  - Mapk1
  - Spdef
  - Mtch1
  - Alpha-re
  - GSK3A
  - tkd
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Ras64B
  - Ras85D
  - ar
  - Akt
  - era
  - MKP-4
  - p38b
  - rl
  - mapP
  - Dsor1
  - Mtk
  - sgg
  - gskt
  - Erk7
  - foxo
  - Tor
  - Wnt5
  - Wnt4
  - wg
  - Cancer
---
